Regulus Therapeutics
RGLSRegulus Therapeutics Inc. or Regulus (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals …
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2023-2025
All insider trades at Regulus Therapeutics
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 6/3/2025 | Buy | Klassen, Preston | President & Head of R & D | $8.0 | $95,852 |
| 1/30/2025 | Buy | Baltimore, David | Director | $1.1 | $20,787 |
| 1/30/2025 | Buy | Hagan, Joseph P. | Chief Executive Officer | $1.1 | $54,260 |
| 1/14/2025 | Sell | Calsada, Crispina | Chief Financial Officer | $1.3 | $6,427 |
| 1/14/2025 | Sell | Aker, Christopher Ray | Sr. VP & General Counsel | $1.3 | $6,427 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)